XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and License Agreements - Novartis (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Aug. 31, 2022
Dec. 31, 2021
Collaborative Agreements disclosures              
Revenue from contract with customer $ 113,425 $ 15,375 $ 246,447 $ 67,615      
Contract with customer liability 63,904 53,811 63,904 53,811 $ 50,211   $ 92,068
Revenue recognized, previously deferred 3,929 7,337 9,534 43,961      
Milestone payments plus royalties on the commercial sales | Novartis              
Collaborative Agreements disclosures              
Potential milestone payment 199,500   199,500        
Revenue recognized, previously deferred     5,000        
License and milestone fees              
Collaborative Agreements disclosures              
Revenue from contract with customer 51 $ 7,382 15,122 45,247      
License and milestone fees | Novartis              
Collaborative Agreements disclosures              
Deferred revenue 700   700        
Revenue recognized, previously deferred       2,800      
Research and development support              
Collaborative Agreements disclosures              
Revenue from contract with customer $ 855   $ 1,310 831      
Research and development support | Novartis              
Collaborative Agreements disclosures              
Revenue from contract with customer       $ 2,800      
Deferred revenue           $ 2,800